Viridian Therapeutics, Inc. (VRDN)

Market Cap	933.93M
Revenue (ttm)	347,000
Net Income (ttm)	-216.66M
Shares Out	52.59M
EPS (ttm)	-5.14
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	832,301
Open	17.78
Previous Close	17.76
Day's Range	17.78 - 18.98
52-Week Range	10.93 - 39.00
Beta	1.05
Analysts	Strong Buy
Price Target	39.45 (+112.21%)
Earnings Date	Nov 13, 2023

About VRDN

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-002 and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-004, a discovery-stage therapeut...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 86
• Stock Exchange: NASDAQ
• Ticker Symbol: VRDN

Financial Performance

In 2022, VRDN's revenue was $1.77 million, a decrease of -40.20% compared to the previous year's $2.96 million. Losses were -$129.87 million, 63.5% more than in 2021.

Analyst Forecast

According to 11 analysts, the average rating for VRDN stock is "Strong Buy." The 12-month stock price forecast is $39.45, which is an increase of 112.21% from the latest price.

Price Target

$39.45

(112.21% upside)

Analyst Consensus: Strong Buy